NLRP3 and gout: In this context, colchicine, which is the standard of therapy for treating acute gouty arthritis, was found to inhibit the activation of the ATP-induced P2 × 7 receptor, which activates NLRP3 inflammasome by allowing potassium efflux from cytoplasm.